<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01225705</url>
  </required_header>
  <id_info>
    <org_study_id>UKB-2009-MED-I-JKR-01</org_study_id>
    <secondary_id>2009-015904-24</secondary_id>
    <nct_id>NCT01225705</nct_id>
  </id_info>
  <brief_title>Safety Study of Raltegravir in HIV/HCV Co-infected Patients</brief_title>
  <official_title>An Open, Prospective Study to Compare the Safety and Efficacy of Raltegravir vs. Atazanavir / Ritonavir, Both in Combination With Tenofovir DF and Emtricitabine, in the Treatment of HIV-infection in ART Naive Subjects With HCV Co-infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr. Axel Baumgarten, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Christoph Stephan, Frankfurt/M</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Stefan Esser, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Keikawus Arastéh, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prof. Dr. Hans-Jürgen Stellbrink, Hamburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Thomas Lutz, Frankfurt/M</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Jörg Gölz , Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current European AIDS Clinical Society (EACS) guidelines for the treatment of HIV infection
      recommend a combination antiretroviral regimen composed of two nucleoside reverse
      transcriptase inhibitors plus a ritonavir boosted protease inhibitor or a non-nucleoside
      reverse transcriptase inhibitor.

      The non-nucleoside reverse transcriptase inhibitors licensed for naïve patients - nevirapine
      and efavirenz - have both been asociated with increased rates of hepatotoxicity (nevirapine)
      and CNS toxicity (efavirenz) in HIV/HCV co-infected patients. Although PI-based therapy has
      dramatically reduced morbidity and mortality, it has been limited by complex dosing regimens
      and toxicities, leading to adherence challenges. Varying degree of liver insufficiency may
      necessitate pharmacokinetic monitoring of the protease inhibitor and may necessitate dose
      adjustments. In HIV/HCV co-infected patients HAART based on another class of antiretrovirals
      than NNRTI or PI may thus offer advantages with regard to adverse events and thus long-term
      efficacy.

      The overall intention of this trial is to examine in a non-inferiority design the safety and
      efficacy of a raltegravir based HAART with a standard-of-care HAART in HIV-/HCV co-infected
      patients. The standard of care used in this study will be atazanavir/ritonavir. All patients
      will in addition receive a fixed combination of tenofovir and emtricitabine.

      The primary end-point is the rate of hepatotoxic events, defined by ALT elevations.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no pts recruited
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary objective</measure>
    <description>there is no difference in the rate of grade 1/2, or 3/4 ALT elevations
there is a higher incidence of grade 1 - 4 hyperbilirubinemias in the ATV/r arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary objectives</measure>
    <description>Other parameters of safety and efficacy will be compared between both arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>45 patients will receive open label raltegravir, in addition to the common backbone tenofovir and emtricitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atazanavir/ritonavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>45 patients will receive open label atazanavir/ritonavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>Patients will be randomized 1:1 to either the experimental or the active control arm</description>
    <arm_group_label>Raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir/ritonavir</intervention_name>
    <description>Patients will be randomized 1:1 to either the experimental or the active control arm</description>
    <arm_group_label>Atazanavir/ritonavir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV and Hepatitis C co-infected patients

          -  indication for HAART according to current German-Austrian guidelines

          -  HAART naive

          -  no primary NRTI / Integrase / PI associated resistance mutation according to the
             Stanford algorithm at screening; every patient MUST have a genotypic resistance assay
             prior baseline available (&lt; 6 months prior to baseline)

          -  women of childbearing age: negative pregnancy test

          -  ability to sign written informed consent

        Exclusion Criteria:

          -  advanced liver cirrhosis Child-Pugh B or C or decompensated liver disease

          -  Pegylated interferon / ribavirin or other anti-HCV therapy; planned anti-HCV therapy
             for duration of the study (48 weeks).

          -  acute or chronic hepatitis B infection

          -  acute hepatitis A or other hepatotropic virus infections

          -  any other chronic liver disease such as alcohol abuse or hemosiderosis

          -  use or planned use (for the duration of the study, 48 weeks) of rifampicin, St. John´s
             wort and drugs that are metabolized via the cytochrome P450 system with a narrow
             therapeutic PK-range such as astemizole, terfenadine, cisapride, pimozide, chinidin,
             bepridil, triazolam, midazolam, ergotamine, dihydroergotamin, ergometrine,
             methyl-ergometrine. FOR OTHER COMEDICATIONS please consult with the SPC of Raltegravir
             (Isentress®), Atazanavir (Reyataz®), Ritonavir (Norvir®), your hospital pharmacist,
             www.hiv-drug-interactions.org or the principal investigator in case of uncertainty.

          -  new AIDS defining event, except for Kaposi sarcoma, &lt; 1 months prior to screening

          -  malignancy, except for Kaposi sarcoma, with current radio- or chemotherapy

          -  history of organ transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Auguste Viktoria Hospital (AVK)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxiszentrum Kaiserdamm</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice Dupke, Carganico, Baumgarten</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine I, Bonn University</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infektiologikum Frankfurt</name>
      <address>
        <city>Frankfurt / Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Frankfurt</name>
      <address>
        <city>Frankfurt / Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infektionsmedizinisches Centrum Hamburg (ICH)</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <name_title>Rheinische Friedrich-Wilhelms-Universität Bonn, Germany</name_title>
    <organization>Bonn University</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

